

is now available, with **NEW**
simplicity, syringe and support



NEW simplicity

Both chronic kidney disease (CKD) and hypertension (HT) indications* are now on the Semintra 4 mg/ml presentation¹

- Makes it **easier to treat** these common conditions **individually**, or when **present together**
- More **flexibility** for you and your clients
- Use the charts on the reverse of this sheet to advise on **dosing and bottle duration** for your patients with CKD and/or HT[#]



NEW syringe

Convenient **ml-calibrated** syringe

- Helps to **ensure accurate dosing** by pet owners and **patient safety**
- Allows **titration of dosing** for patients with HT[#]



NEW support

Innovative packaging update with QR code that links to online **pet owner resources**

- Encourages **pet owner compliance** with easy-to-follow '**How to use**' video
- **User-friendly digital leaflet**, including features such as read function, text search, adaptation of font sizes and PDF download
- New packaging will continue to **include a paper leaflet** for pet owners who prefer that format



Semintra 4 mg/ml provides convenient once-daily dosing for CKD* and/or HT#



	Body weight (kg)							
	1	2	3	4	5	6	7	8
	Dose (ml/day)							
CKD* (Dose 1 mg/kg)	0.25	0.5	0.75	1.0	1.25	1.5	1.75	2.0
HT +/- CKD* (Dose 2 mg/kg)	0.5	1.0	1.5	2.0	2.5	3.0	3.5	4.0



Semintra 4 mg/ml bottle duration#

Bottle size	Body weight (kg)							
	1	2	3	4	5	6	7	8
	Approximate number of days							
30 ml for CKD*	120	60	40	30	24	20	17	15
30 ml for HT +/- CKD*	60	30	20	15	12	10	8	7
100 ml for CKD*	400	200	133	100	80	67	57	50
100 ml for HT +/- CKD*	200	100	66	50	40	33	28	25



Talk to your Boehringer Ingelheim representative for more information about **Semintra**, the first and only liquid solution for the management of CKD and/or HT in cats*

*Semintra is licensed for the reduction of proteinuria associated with CKD in cats and for the treatment of systemic HT in cats.

#Dosing guidelines (based on EMEA approved label): When treating concomitant CKD+HT, dosing to be done in accordance with HT dosing. After 4 weeks, the dosage of telmisartan may be reduced in cats with systolic blood pressure (SBP) of less than 140 mmHg (in 0.5 mg/kg increments) at the discretion of the veterinarian. If SBP increases over the course of the disease, the daily dose may be increased again up to 2 mg/kg. Target SBP range is between 120 and 140 mmHg. The recommended minimum effective dose when treating concomitant CKD and HT is 1 mg/kg.

Reference: 1. Semintra Summary of Product Characteristics (SPC). European Medicines Agency. Accessed August 2025.



SEMINTRA® is a registered trademark of Boehringer Ingelheim Animal Health Netherlands bv, Basisweg 10, 1043 AP Amsterdam, tel: 020 - 799 6959, vetmedica.nl@boehringer-ingelheim.com, support.boehringer.nl. Scan the QR code or view the package inserts of our products at www.boehringer-ingelheim.nl/hond. © 06/2025 - All rights reserved. Use medicines responsibly. 1152550

